Trientine Hydrochloride
PreclinicalSmall molecule
Trientine Hydrochloride is one of 11 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Proliferative Diabetic Retinopathy
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Vabysmo
RocheApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Sandostatin
Sun PharmaApproved
Decadron
AAspen Global Incorporated
Approved
Arcoxia
NovartisPreclinical
Avastin
RochePreclinical
RRG001
LLi Xiaorong
Phase 1
Intravitreal Injection of Conbercept
SSun Yat-sen University
Preclinical
Trientine Hydrochloride
UUniversity of British Columbia
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trientine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of British Columbia